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Abstract
Background—Toxocariasis results from infection with larval stages of a dog and cat intestinal 
nematode and causes human morbidity. The current US estimate of Toxocara exposure is 13.9% 
(NHANES III 1988–1994).
Methods—We used a multiplex bead based assay (Tc-CTL-1MBA) with purified Toxocara canis 
antigen to estimate Toxocara antibody seroprevalence in serum of 13,509 persons six years and 
older from the National Health and Nutrition Examination Survey (NHANES), 2011–2014 and 
identified seropositivity risk factors. We tested a subset of 500 samples with the T. canis enzyme 
immunoassay used in NHANES III to estimate prior seroprevalence had samples from NHANES 
III been tested by Tc-CTL-1MBA.
Results—The age standardized estimate of Toxocara seroprevalence was 5.0% (95% confidence 
interval [CI], 4.2%–5.8%), lower than previously reported even adjusting for increased Tc-
CTL-1MBA specificity. Risk factors for seropositivity from multiple logistic regression were older 
age (odds ratio [OR], 2.1; 95%CI, 1.1–3.9 in persons 50–59 years old; OR, 1.7; 95%CI, 1.0–2.8 in 
persons 60–69; and OR, 2.6; 95%CI, 1.5–4.7 in persons ≥70 versus persons 6–11), non-Hispanic 
Black race/Hispanic origin (OR, 1.4; 95%CI, 1.0–2.0) versus non-Hispanic White, male sex (OR, 
1.9; 95%CI, 1.6–2.2), living below poverty level (OR, 1.9; 95%CI, 1.4–2.6), households with ≥0.5 
persons per room (OR, 1.3; 95%CI, 1.0–1.6), less than college education (OR, 1.9; 95%CI, 1.5–
2.4), and birth outside the United States (OR, 3.6; 95%CI, 2.6–5.1).
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Conclusions—Toxocara seroprevalence estimates in 2011–14 were lower than in a study from 
NHANES III, 1988–94, but seropositivity risk factors remained the same and should continue to 
be the focus of prevention efforts.
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Background
Human toxocariasis is caused by inadvertent infection and migration of Toxocara species 
larvae. The larvae are immature Toxocara canis and cati, intestinal nematodes of dogs and 
cats. Severity ranges from covert with non-specific asthma-like symptoms to marked 
eosinophilia, fever, and hepatomegaly in visceral toxocariasis (VT), retinal scarring and 
visual impairment in ocular toxocariasis (OT), and cerebral vasculitis, meningitis, 
encephalitis, myelitis, and seizures in neurotoxocariasis (NT)[1]. Prevalent in the tropics and 
sub-tropics and in less industrialized countries, toxocariasis is also associated with 
socioeconomically disadvantaged populations in industrialized countries [1].
In the US National Health and Nutrition Examination Survey (NHANES) I (1971–1973), 
seroprevalence of antibody to T. canis excretory-secretory antigen (TES-Ag) expressed by 
infective larvae was 4.6%–7.3% among children aged 1–11 years [2]; seroprevalence was 
13.9% among persons aged ≥6 years in NHANES III (1988–1994)[3]. In NHANES III, ages 
20–39, non-Hispanic Black race/ethnicity, male sex, living below the poverty level, high 
school education or less compared with at least some college, elevated blood lead levels, dog 
ownership, rural residence, birth outside the US, and residence in regions outside the West 
were predictors of Toxocara seropositivity. These results suggest elevated exposure to 
Toxocara in the US population, particularly in certain subpopulations, but must be 
interpreted with caution. TES-Ag enzyme immunoassay (EIA) used in NHANES I and III is 
reliable [4] but cross-reacts with other helminths [5, 6]. Furthermore, these estimates are 
over 17 years old. To provide current estimates of national seroprevalence using improved 
laboratory methods and to identify subpopulations with higher risk, we employed a 
multiplex bead-based assay with purified recombinant Tc-CTL-1 antigen (Tc-CTL-1MBA) 
to test a nationally representative sample of individuals surveyed in 2011–2014.
Methods
Study design and participants
NHANES is a nationally representative, cross-sectional survey conducted by the National 
Center of Health Statistics (NCHS). Since 1999, approximately 5000 individuals have been 
interviewed each year and have undergone health examination and laboratory testing. In 
2011–2014, non-Hispanic Asians, Hispanics, non-Hispanic blacks, as well as non-Hispanic 
whites and others at ≤130% poverty level were oversampled to increase reliability and 
precision of health status indicator estimates for these subgroups. Survey design details are 
found elsewhere [8].
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Serum samples
Tested sera were from individuals ≥6 years old in the NHANES 2011–2014 survey that were 
previously used for other tests, and if sera remained, were returned as surplus specimens to 
the NCHS repository.
Ethical approval
The overall NHANES 2011–2014 survey (Protocol #2011-17) and this study (Protocol 
#2014-13) were approved by the NCHS Ethics Review Board.
Detection of Toxocara antibody
Samples were probed for antibodies against recombinant T. canis excretory-secretory 
antigen, Tc-CTL-1, by multiplex bead-based assay (Tc-CTL-1MBA). Details of antigen 
identification, expression, and antibody probing are described elsewhere [4]. Briefly, Tc-
CTL-1 was coupled to MagPlex Magnetic Microspheres (Luminex) using 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride-N-hydroxysulfosuccinimide reactions. 
Next, 50 μL of these beads were incubated with 50 μL of test sera diluted 1:100 in 
phosphate-buffered saline (PBS)–0.3%Tween/5% milk in each well of a Costar 96-well 
black, round-bottom plate (Fisher Scientific) at room temperature, with shaking at 800 rpm 
for 30 minutes. Beads underwent 2 minutes of magnetic separation followed by a wash of 2 
cycles of instillation of 100 µL of PBS–0.3% Tween for 40 seconds in a Biotek magnetic 
washer ELx50. Detection of antibody bead complex was performed through 30 minutes of 
incubation with 50µL per well of 1:200 biotinylated mouse anti-human immunoglobulin G 
(clone H2, affinity purified, Southern Biotech) in PBS-1% BSA, 0.05% NaN3, followed by 
wash as before, and 30minutes of incubation with 50µL per well of 1:250 Streptavidin, R-
phycoerythrin conjugate (Invitrogen) diluted in PBS-1% BSA, 0.05% NaN3. Beads were 
resuspended with 100 µL per well of PBS-1% BSA, 0.05% NaN3. Mean fluorescence 
intensity (MFI) for each well was determined by BioPlex manager software, version 6.02 
(BioRad). A cut-off (23.1 MFI) based on ROC curve analysis determined positive and 
negative results.
Recognizing TES-AgEIA (used in NHANES III) has 78% sensitivity and 92% specificity 
[7], whereas Tc-CTL-1MBA has 90% sensitivity for VT and 99% specificity [4], to compare 
seroprevalence estimates in NHANES III and this study, we randomly selected 250 samples 
within each group of sera determined positive or negative by Tc-CTL-1MBA from those 
available in NHANES 2013–2014, and probed for antibodies using TES-AgEIA. Detailed 
methods are found elsewhere [3]. In brief, sera diluted 1:100 in PBS-0.05%Tween was 
placed into 96-well Immulon II HB flat bottom plates sensitized with TES-Ag diluted 
1:2000 in 0.1M NaHCO3/Na2CO3. Antigen-antibody complexes were detected using anti-
IgG enzyme conjugate and visualized with tetramethylbenzidine substrate read at 450nm. 
Cutoffs were determined by averaging optical density (OD) readings for four standards at a 
1:32 titer (determined to be the cutoff for being positive from a reference ELISA), and 
dividing this value by the mean of four high positive control OD values. For each sample, a 
ratio was calculated by dividing the sample OD value by the mean of the high positive 
control. This ratio was compared with the cutoff; values above the cutoff were considered 
positive.
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Statistical Analysis
Analysis was performed with R statistical software [9] and the survey package [10, 11]. We 
analyzed data on available demographic characteristics putatively related to Toxocara 
exposure as in NHANES III [3], and also a self-reported asthma diagnosis given the 
hypothesized association between Toxocara exposure and asthma symptoms [19]. We used 
definitions from NHANES III for factors; age was categorized into those aged 6–11, 12–19, 
20–29, 30–39, 40–49, 50–59, 60–69, and ≥70 years. Self-reported race/Hispanic origin was 
categorized as non-Hispanic white, non-Hispanic black, non-Hispanic Asian (not available 
in NHANES III), Mexican-American, and all others (individuals not self-identifying into 
any previous group including other Hispanics and those reporting multiple races). Poverty 
level (the ratio of family income divided by a poverty threshold specific for family size using 
guidelines from the US Department of Health and Human Services) was categorized as <1 
(below poverty) or ≥1 (at or above poverty) [12]. Crowding index (the total number of 
household residents divided by rooms in the household) was categorized as <0.5, 0.5–0.99, 
or ≥1 persons per room (PPR). Head of household education (the last year of school 
completed by the head of household) was grouped into no high school (<9th grade), some 
high school (9–12 grade), high school graduate, and at least some college.
The complex survey design was specified using survey design variables for the number of 
strata and primary sampling units. Examination weights were incorporated to account for 
oversampling and nonresponse to interview and examination. The outcome was defined as 
antibody assay positive or negative. Estimates were standardized by age groups mentioned 
above to the 2000 US census population and calculated for each level of the previously 
described factors for the total population and stratified by race/Hispanic origin. 
Seroprevalence and 95% confidence intervals were estimated using the Korn and Graubard 
method [13]. Estimates based on <10 sample persons positive for Toxocara, a relative 
standard error (RSE) >30%, or standard errors with <10 degrees of freedom were designated 
potentially unstable. To increase stability of the estimates, those age 60–69 and ≥70 were 
combined when comparing age specific estimates and when examining a linear test for trend 
across age groups. To screen for independent predictors of Toxocara seropositivity, t tests 
were performed for each factor level relative to the reference level (the level with lowest 
risk) [14] for the total population and stratified by race/Hispanic origin using age-
standardized estimates. Factors with significant differences in the previous analyses were 
included in a multiple logistic models to identify potential independent predictors of positive 
antibody. P-values <0.05 were considered statistically significant. No multiple comparison 
corrections were made.
Of 23,832 persons ≥6 years old in NHANES 2011–2014, 70.2% agreed to the interview and 
96.3% of those interviewed were examined. Of those persons examined, 83.8% (13,509) had 
serologic specimens obtained and available for testing. Differences in availability were 
found by age group (p<0.001), race/Hispanic origin (p<0.001), poverty level (p<0.001), 
crowding index (p<0.001) and place of birth (p<0.001) by χ2 testing (Supplemental Table 
1). These factors were used to calculate adjusted sampling weights [15]. All analyses were 
repeated using the adjusted weights and compared to the original results to determine the 
impact of unavailable samples.
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To determine degree of correlation between Tc-CTL-1MBA and TES-AgEIA, we performed 
χ2 testing from each assay for the 250 samples randomly selected from those designated 
positive or negative by Tc-CTL-1MBA. Sample size was determined by χ2 power 
calculation (effect size w=0.2, df=1, α=0.05, and β=0.2 resulting in n=196, rounded up to 
250).Within samples positive by TES-AgEIA, the proportion positive by Tc-CTL-1MBA 
was multiplied against seroprevalence by TES-AgEIA as the most conservative estimate of 
seroprevalence had Tc-CTL-1MBA been used.
Results
Estimates of Toxocara seroprevalence by age and race/Hispanic origin
Estimated Toxocara seroprevalence among US persons ≥6 years old (n=13,509) was 5.1% 
(95%CI 4.3%–5.9%) unadjusted and 5.0% (95%CI 4.2%–5.8%) age standardized to the 
2000 US census population. Seroprevalence increased significantly with age from 3.0% in 
those age 6–11 to 4.8%–6.4% in all age groups ≥30 years (p<0.05, test for linear trend with 
age group p<0.001) (Table 1). When stratified by race/Hispanic origin, prevalence increased 
with older age among non-Hispanic Blacks (3.5% age 6–11 compared with 10.4% among 
those age 50–59 and those age ≥60, P<0.001; test for linear trend p<0.001), and in some age 
strata for non-Hispanic Asians (2.1% in those age 6–11 compared with 6.1%, P <0.05 and 
19.7%, P<0.001; in those age 40–49 and age ≥60, respectively, linear test for trend p<0.001). 
Among non-Hispanic whites, there was no significant differences between individual age 
groups and the reference group (p>0.20) and no significant linear trend with age group 
(p=0.05). Among Mexican Americans there were some individual differences (3.0% in those 
age 6–11 compared with 8.7%, P<0.05; and 8.9%, P<0.05 in those age 20–29 and 40–49, 
respectively) but no significant linear trend with age group. There is insufficient sample size 
to make stable estimates for some age and race and Hispanic origin subgroups (unstable 
estimates are noted in Table 1) and insufficient power for some subgroup comparisons.
Predictors of Toxocara seropositivity on univariate analysis
Age standardized seroprevalence varied by race/Hispanic origin (6.6% in non-Hispanic 
Blacks, 7.3% in non-Hispanic Asians, and 6.1% in Mexican Americans compared with 3.7% 
in non-Hispanic Whites; P<0.001, P<0.001, and P<0.05 respectively), male sex (6.2% vs 
3.8% among females, P<0.001), income below poverty level (10.2%) compared with at or 
above the poverty level (3.9%, P<0.001), greater household crowding (0.5–0.99 PPR: 5.6% 
and ≥1 PPR: 10.5% vs <0.5 PPR: 3.5%, P<0.001), less than a college education (high school 
graduate: 6.4%, some high school: 7.8%, and less than high school: 11.1% vs at least some 
college: 3.4%, P<0.001), and birth outside the US (11.9% vs 3.7%, P<0.001) (Table 2). 
Within race/Hispanic origin strata, male sex (P<0.01) remained associated with elevated 
seroprevalence except in Mexican Americans. Similarly, income below poverty level, high 
school graduation, and less than high school education (P<0.05) compared to at least some 
college remained associated with elevated seroprevalence except in Non-Hispanic Asians. 
Birth outside the US (P<0.05) was associated with elevated seroprevalence except in Non-
Hispanic Whites. Household crowding with ≥1 PPR compared to households with <0.5 PPR 
was associated with higher seroprevalence in non-Hispanic Whites and Mexican Americans 
(P<0.05). An asthma diagnosis was associated with lower prevalence compared to those 
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without asthma only in non-Hispanic Blacks (4.0% vs 7.1%, P<0.001). The sample size was 
insufficient to calculate stable estimates for some subgroups and power was insufficient for 
some subgroup comparisons (Table 2).
Independent risk factors for Toxocara seropositivity
To identify independent factors associated with seropositivity, we performed multiple 
logistic regression on factors associated with seropositivity in univariate analysis. Persons 
50–59, 60–69, and ≥70 years old were more likely to be seropositive (OR, 2.1; 95%CI, 1.1–
3.9; OR, 1.7; 95%CI, 1.0–2.8; and OR, 2.6; 95%CI, 1.5–4.7; respectively) compared to 
those 6–11 years old (Table 3). Non-Hispanic Blacks were more likely (OR, 1.4; 95%CI, 
1.0–2.0) and Mexican Americans less likely (OR, 0.6; 95%CI, 0.4–1.0) to be seropositive 
compared to non-Hispanic Whites. Of the remaining factors, male sex (OR, 1.9; 95%CI, 
1.6–2.2), living below poverty level (OR, 1.9; 95%CI, 1.4–2.6), household crowding with 
≥0.5 PPR (OR, 1.3; 95%CI, 1.0–1.6), head of household having less than a college 
education (OR, 1.9; 95%CI, 1.5–2.4), and birth outside the US (OR, 3.6; 95%CI, 2.6–5.1) 
were associated with higher seroprevalence.
Impact of availability of sera by subgroup
A comparison between each set of seroprevalence estimates using weight adjustments for 
each factor with significant differences in availability within levels was made against 
unadjusted weights. A maximal difference of 1.3% amongst all comparisons was observed 
(Supplemental Results).
Correlation between results of testing with TES-AgEIA and Tc-CTL-1MBA
Results from samples tested with both TES-AgEIA and Tc-CTL-1MBA were significantly 
correlated (P<0.0001). Of 249 available sera positive for Toxocara antibody by Tc-
CTL-1MBA, 208 (83.5%) were positive by TES-AgEIA. Of 250 sera negative for Toxocara 
antibody by Tc-CTL-1MBA, 178 (71.2%) were negative by TES-AgEIA. Of those TES-
AgEIA positive, 74.3% were positive by Tc-CTL-1MBA (Table 4). This proportion positive 
was multiplied against the seroprevalence estimate (13.9%) from NHANES III resulting in a 
conservative estimated seroprevalence of 10.3% among persons age ≥6 years if the current 
assay had been used.
Discussion
This study updates estimates of seroprevalence of Toxocara antibody in the US and 
identifies subpopulations at risk for exposure by examining Toxocara specific antibodies in a 
nationally representative sample of individuals surveyed during 2011–2014 with a specific 
assay utilizing purified recombinant Tc-CTL-1 antigen. Overall age standardized prevalence 
of 5.0% (95%CI 4.2%–5.8%) is lower than 13.9% (95%CI 12.5%–15.3%) observed in 
NHANES III among those age 6 and older measured by TES-AgEIA [3]. Similarly, the age 
specific estimate of 3.0% (95%CI 1.9%–4.5%) in children 6–11 years old is also lower than 
the estimates ranging from 4.6% to 7.3% in children 1–11 years old in a previous study from 
NHANES I measured by TES-AgEIA [2]. When accounting for the difference in test 
characteristics between the two assays, overall seroprevalence was estimated to be 10.3% in 
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NHANES III among those age 6 and older if the current assay had been used. Even with this 
conservative adjustment that does not account for samples both TES-AgEIA negative and 
Tc-CTL-1MBA positive, these estimates remain higher than the 2011–14 estimate of 5.0% 
overall, suggesting decreased exposure to Toxocara over 17 years in the US population.
In the current study, older adults (≥50 years of age) had higher Toxocara seroprevalence than 
children 6–11 years old, whereas in NHANES III, younger adults 20–39 years old had 
higher seroprevalence compared to children 6–11 years old. If Toxocara antibodies are long-
lived as previous studies have inferred [16, 17], the apparent shift towards greater 
seroprevalence among older age groups in this study could reflect aging of a cohort of 
individuals with greater past exposure to Toxocara. Further supporting this possible cohort 
effect is decreased Toxocara seroprevalence in adults 40–49 years old relative to contiguous 
age groups in NHANES III with a corresponding decrease in prevalence among adults 60–
69 years old in this current study (Table 3) occurring 17 years after completion of NHANES 
III.
Although we observed lower overall seroprevalence and differences in age groups at higher 
risk in this study, we identified similar risk factors for Toxocara seropositivity amongst 
shared factors described in NHANES III. Prevalence remains higher among non-Hispanic 
Blacks and lower among Mexican Americans. Furthermore, birth outside of the US, male 
sex, poverty, and less than college education are again identified as possible risk factors.
This study introduces new findings. It estimates Toxocara seroprevalence among non-
Hispanic Asians in the US for the first time. On univariate analysis, seroprevalence was 
higher among non-Hispanic Asians compared to non-Hispanic Whites, but this association 
was confounded by place of birth. Over 75% of the non-Hispanic Asian population based on 
NHANES data were born outside the US and in multiple logistic models adjusted for place 
of birth, non-Hispanic Asian race/ethnicity was no longer associated with higher 
seroprevalence. We note crowding, a possible correlate of lower socioeconomic status [18], 
as a risk factor for seropositivity, which was not noted on multiple logistic regression in 
NHANES III. Contrasting with a previous study that found higher seroprevalence with an 
asthma diagnosis in children 4–6 years old [19], we found lower seroprevalence in those 
with an asthma diagnosis among non-Hispanic Blacks. While consistent with the “hygiene 
hypothesis” [20] in an older population, this finding must be interpreted with caution as it is 
limited to one subgroup.
This antibody-based study is unable to differentiate between recent or remote infection [17]. 
Furthermore, 16.2% of subjects undergoing examination did not have specimens obtained 
and available for testing. In particular, differences in availability of specimens varied 
significantly in subgroups by age, race/Hispanic origin, poverty, crowding, and place of birth 
(Supplemental Table 1). Sample weights were adjusted to account for nonresponse but the 
adjustment had minimal impact on seroprevalence estimates (differences ≤1.3%), suggesting 
minimal nonresponse bias.
To facilitate comparison of results, we estimated the seroprevalence for NHANES III if 
samples had been tested using Tc-CTL-1MBA. Adjustments are based on a subset of 
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specimens, which may not represent the entire US population. Furthermore, higher 
specificity of Tc-CTL-1MBA compared to TES-AgEIA[4] may reflect detection of only T. 
canis specific antibody in Tc-CTL-1MBA in contrast to non-specific Toxocara antibody 
reflecting infection with T. canis or cati in TES-AgEIA. TES-AgEIA has not been tested 
against sera with antibodies exclusive to T. cati, whose role in human infection is unknown, 
but thought to be important. In addition, variables such as pet ownership and location of 
residence were only available in NHANES III. Blood lead level and occupation were 
available in NHANES 2011–2014, but these data were too small of a subset or nonspecific 
to allow inclusion in the current study.
Despite the above mentioned caveats, we confirm risk factors associated with exposure that 
can cause a disease with severe morbidity. These risk factors can guide healthcare providers 
in evaluation of possible toxocariasis in patients as well as inform public health interventions 
to reduce exposure in populations at risk, such as encouraging hand washing after contact 
with soil, reducing soil contamination by dog and cat feces where at-risk populations live, 
and treating dogs and cats with antihelminths to reduce Toxocara burdens [3].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary
Evidence of human exposure to Toxocara, an intestinal nematode of dogs and cats, was 
lower based on a national serosurvey conducted from 2011 through 2014 than in a survey 
conducted 17 years prior, but remained associated with specific risk groups.
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Table 3
Risk factors for Toxocara seropositivity, as estimated with a full logistic regression model for all persons ≥ 6 
years of age, NHANES 2011–2014
Factor OR (95% CI)
Age (years)
  6–11 Ref
  12–19 1.1 (0.6, 1.9)
  20–29 1.4 (0.8, 2.4)
  30–39 1.3 (0.7, 2.3)
  40–49 1.6 (0.9, 2.7)
  50–59 2.1 (1.1, 3.9)*
  60–69 1.7 (1.0, 2.8)*
  ≥70 2.6 (1.5, 4.7)**
Race/Hispanic Origin
  Non-Hispanic White Ref
  Non-Hispanic Black 1.4 (1.0, 2.0)*
  Non-Hispanic Asian 0.7 (0.5, 1.1)
  Mexican American 0.6 (0.4, 1.0)*
  Other Hispanic and Other Race 1.1 (0.8, 1.8)
Sex
  female Ref
  male 1.9 (1.6, 2.2)***
Poverty level
  below 1.9 (1.4, 2.6)***
  at or above Ref
Crowding index (persons per room)
  ≥0.5 1.3 (1.0, 1.6)*
  <0.5 Ref
Head of household education
  less than college 1.9 (1.5, 2.4)***
  at least some college Ref
Place of birth
  other 3.6 (2.6, 5.1)***
  United States Ref
***
P < 0.001,
**
<0.01,
*
<0.05
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Table 4
2 × 2 table of results of comparative testing with the TES-AgEIA in each group of 249 and 250 randomly 
sampled sera found positive or negative, respectively, by Tc-CTL-1MBA.
Tc-CTL-1MBA
+ −
TES-AgEIA
+ 208 74.3%† 72 25.7%† 280
83.5%‡ 28.8%‡
− 41 18.7%† 178 81.3%† 219
16.5%‡ 71.2%‡
249 250
χ2=150 P<0.0001
†
Percentage positive or negative by Tc-CTL-1MBA within a row specifying all positive or negative TES-AgEIA results.
‡
Percentage positive or negative by TES-AgEIA within a column specifying all positive or negative Tc-CTL-1MBA results.
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